TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17036619
Drug: Exercise and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise and cognitive-behavioral therapy
Study: 12707157
Drug: Clonidine 15
Normalized name: chlorthalidone-clonidine 15 mg-0.1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 15 micro g with bupivacaine 6 mg
Study: 8574749
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 5 mg/kg intravenous infusion over 180 min
Study: 6452297
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin (1%) in a new penetrative vehicle
Study: 25669083
Drug: Intercostal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal analgesia (ICA) with 2 ml x hr(‐1) of 0.2% ropivacaine and intravenous fentanyl (0.25 x μg(‐1). kg(‐1) x hr(‐1))
Study: 25669083
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with 2 ml x hr(‐1) of 0.2% ropivacaine and intravenous fentanyl (0.25 x μg(‐1). kg(‐1) x hr(‐1))
Study: 19001265
Drug: Intralymphatic allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic allergen administration (3 injections over 2 months, cumulative allergen dose 3,000 SQ-U)
Study: 19001265
Drug: Intralymphatic allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic allergen administration
Study: 19001265
Drug: s.c. immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. immunotherapy (54 injections over 3 years, cumulative allergen dose 4,031,540 SQ-U)
Study: 16280777
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CyA) 1.5 mg/kg twice daily
Study: 16280777
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 100 mg 3 times daily
Study: 12182757
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of intravenous erythromycin
Study: 31414269
Drug: Sildenafil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (0.5 mg/kg every 6 hours)
Study: 25835642
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (600μg)
Study: 25835642
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin (1mL of 10IU)
Study: 19805689
Drug: Augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented therapy (intensive postinduction treatment)
Study: 8326971
Drug: Anistreplase administered
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase administered before admission (prehospital group)
Study: 8326971
Drug: Anistreplase administered
Normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase administered in the hospital (hospital group)
Study: 27522312
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 2 ml only (control)
Study: 20695899
Drug: Elemental diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental diet treatment
Study: 18192787
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of T. vaginalis
Study: 2580179
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg
Study: 4010387
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 75 mg pirlindol daily for two weeks
Study: 4010387
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pirlindol (single dose)
Study: 4010387
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 75 mg pirlindol (after one week treatment)
Study: 4010387
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg and 225 mg pirlindol (superimposed dosage on days 8 and 15)
Study: 31060037
Drug: Water Resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Resistance Therapy (WRT)
Study: 24136153
Drug: Darexaban 30
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 30 mg qd
Study: 22952213
Drug: Darexaban 30
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 30 mg bid
Study: 24136153
Drug: Darexaban 60
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 60 mg qd
Study: 26052866
Drug: Darexaban 60
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 60 mg bid
Study: 26052866
Drug: Darexaban 120
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 120 mg qd
Study: 26052866
Drug: Warfarin qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin qd
Study: 26052866
Drug: Darexaban (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban (all doses)
Study: 23584270
Drug: Gel group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel group (control)
Study: 31627998
Drug: Bisoprolol 8mg
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol 8mg transdermal patch at bedtime
Study: 30782208
Drug: Gyejigachulbutang (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gyejigachulbutang (2.5 g three times a day for 4 weeks)
Study: 27326445
Drug: Prasugrel (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (titrated dose)
Study: 11516001
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants with overdentures
Study: 3345278
Drug: Atracurium (effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (effective doses)
Study: 20492850
Drug: Aspirin 1000
Normalized name: aspirin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1000 mg/d
Study: 18446591
Drug: School-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based administration of preventive asthma medications with dose adjustments according to NHLBI guidelines and a home-based ETS reduction program utilizing motivational interviewing principles.
Study: 16770112
Drug: Letrozole (Femara
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (Femara tablet 2.5 mg)
Study: 12727970
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy with Premarin or a mixture of estrone and equilin sulfates for 3 months
Study: 7943832
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus fentanyl (0.2, 0.8, 1.5, 3.0, and 4.5 ng/ml)
Study: 7943832
Drug: Propofol plus
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol plus fentanyl (greater than 3 ng/ml)
Study: 28708736
Drug: Mifepristone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 1200 mg daily for 7 days
Study: 19085526
Drug: Internet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet treatment
Study: 15498183
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg three times daily for 3 months (Group Aa)
Study: 15498183
Drug: Clomiphene 50
Normalized name: clomiPHENE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene 50 mg once daily for 5 days and 3 cycles (Group Ab)
Study: 15498183
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and clomiphene (Group Ac)
Study: 11133901
Drug: Alpha-blocker (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-blocker (3 mg/day prazosin)
Study: 9620105
Drug: Oral sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sulfonylureas
Study: 8131544
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg orally 3 times a day for 15 days
Study: 8131544
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro NAC treatment at 10 micrograms/ml
Study: 2675219
Drug: Morphine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (50 micrograms/kg)
Study: 817373
Drug: Synthetic TRH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic TRH (300 mg/day)
Study: 28367636
Drug: Sensor augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor augmented insulin pump therapy (open loop) for 12 weeks
Study: 25040098
Drug: 3% praziquantel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% praziquantel (PZQ) ointment
Study: 25040098
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle ointment)
Study: 19120432
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Aspart (IAsp) 0.3 U/kg
Study: 15881046
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP)
Study: 11471396
Drug: Contemporary Treatment
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contemporary Treatment Approach (CTA)
Study: 9693393
Drug: Intravenous clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clomipramine (12.5 mg, i.v.)
Study: 9693393
Drug: Oral clomipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clomipramine after i.v. challenge
Study: 2126915
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micrograms, topical corticosteroid)
Study: 2126915
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg, cyclooxygenase inhibitor)
Study: 22430025
Drug: Fluoroscopic-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopic-guided injection
Study: 18606285
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (painted center line, post-delineators)
Study: 15811482
Drug: Vasopressor group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressor group (33 patients) with controlled fluid administration
Study: 15811482
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (32 patients) with fluid administration only
Study: 19732200
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC)
Study: 11821456
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy (SDC)
Study: 11149796
Drug: Permanent magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permanent magnetic field therapy (magnets in the form of patches)
Study: 11149796
Drug: Sham magnet
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham magnet patches (control group)
Study: 1485658
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg terfenadine
Study: 1591463
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablet
Study: 6377715
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of immunoglobulins (Intragam)
Study: 6377715
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no immunoglobulin administration)
Study: 19416932
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination
Study: 12002666
Drug: Timolol monotherapy
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol monotherapy
Study: 19416932
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination to Timolol monotherapy
Study: 17803343
Drug: Topiramate adjunctive
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate adjunctive therapy
Study: 11256837
Drug: Oral doxifluridine
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral doxifluridine (700 mg/m2/day) and leucovorin (20 mg/m2) daily during radiation treatment (n = 14)
Study: 11256837
Drug: Oral doxifluridine
Normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral doxifluridine
Study: 11256837
Drug: Intravenous 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil (5-FU)
Study: 3780584
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l Golytely (GOL)
Study: 3780584
Drug: Balanced Electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Electrolyte Solution (BES)
Study: 24742658
Drug: elevated cFLC
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: elevated cFLC (>57.2 mg/L)
Study: 20496736
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy with ginger moxibustion at Dazhui (GV 14) and Feishu (BL 13) applied once at specified intervals based on seasonal timing.
Study: 20496736
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy with ginger moxibustion at Dazhui (GV 14) and Feishu (BL 13) applied once every other 10 days during 30 days.
Study: 16249929
Drug: Diphtheria-tetanus vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus vaccine (DT) with 40 microg of pertussis toxoid (DTaP40)
Study: 16249929
Drug: Diphtheria-tetanus vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus vaccine (DT) with 20 microg or 40 microg of pertussis toxoid
Study: 16249929
Drug: Diphtheria-tetanus vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus vaccine (DT) alone or with pertussis toxoid
Study: 16249929
Drug: Diphtheria-tetanus vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus vaccine (DT)
Study: 2268862
Drug: Ketoprofen 50
Normalized name: ketoprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 50 mg
Study: 12534583
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg
Study: 8665578
Drug: Ketoprofen 25
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 25 mg (2 x 25 mg)
Study: 1449335
Drug: Enoximone 100
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 100 mg three times a day orally (Group E)
Study: 29862945
Drug: MPT64 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPT64 patch test
Study: 19666152
Drug: Cell-culture-derived influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-culture-derived influenza vaccine (CCIV)
Study: 19673651
Drug: Conventional egg-based
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional egg-based vaccine
Study: 15327583
Drug: Intra-arterial ALA
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial ALA (incremental cumulative doses of 0.5, 1.0, 1.5 and 2.0 mg ml(‐1) min(‐1))
Study: 15327583
Drug: Plasma ALA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma ALA after oral supplementation
Study: 9066509
Drug: Bioresonance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresonance therapy (BIT)
Study: 9066509
Drug: Sham (placebo)
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (placebo) BIT treatment
Study: 3005384
Drug: Captopril, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 200 mg every 12 hours (n = 9)
Study: 3005384
Drug: Enalapril maleate,
Normalized name: Enalapril Maleate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril maleate, 20 mg every 12 hours (n = 11)
Study: 29862568
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication
Study: 25041141
Drug: CVS brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVS brand antacid
Study: 21967854
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1.4 g EPA and DHA)
Study: 20355261
Drug: 6 of
Normalized name: CLN2 RDNA CONSTRUCT DISRUPTING EXON 6 OF CLN2 GENE IN YUCATAN MINIATURE SWINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 of the 9 treatments
Study: 2007669
Drug: Terbinafine, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine, 250 mg twice daily for 6 weeks
Study: 2007669
Drug: Griseofulvin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin, 500 mg twice daily for 6 weeks
Study: 25195020
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to the GermanIMPACT model
Study: 2203327
Drug: MK-212 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-212 (20 mg)
Study: 28397984
Drug: 12-month multifactorial
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month multifactorial intervention by primary care nurses including motivational interviews and individualized physical activity prescriptions.
Study: 26187089
Drug: Friends Helping
Normalized name: Fisherman's Friend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friends Helping Friends program (treatment group)
Study: 23993298
Drug: VesCell therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VesCell therapy
Study: 9767199
Drug: Buprenorphine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8 mg max dose)
Study: 9767199
Drug: Methadone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (60 mg equivalent, free dosing schedule)
Study: 2977280
Drug: Fenfluramine treatment
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine treatment
Study: 30640206
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (2.5 g per day)
Study: 15214873
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once-daily for 5 days
Study: 15214873
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice-daily for 10 days (Control)
Study: 8347731
Drug: Ubenimex (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubenimex (30 mg orally once a day during maintenance therapy)
Study: 2872803
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 to 40 mg daily)
Study: 22302530
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E administration (400 IU/day p.o.)
Study: 7787467
Drug: Optimal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal therapy for acute myocardial infarction
Study: 820214
Drug: Coarse mesh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarse mesh gauze, changed three times daily
Study: 11464350
Drug: Gabapentin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,200 mg
Study: 12734762
Drug: Maprotiline 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline 60 mg daily for 6 months
Study: 17310047
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (continuous insulin infusion to maintain intraoperative glucose levels between 4.4 and 5.6 mmol/L)
Study: 17310047
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (no insulin unless glucose > 11.1 mmol/L)
Study: 10755315
Drug: Cisplatin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (70 mg/m2 on day 1), ifosfamide (1.5 g/m2 on days 1-4), irinotecan (60 mg/m2 on days 1, 8, and 15), with rhG-CSF (1 microg/kg on days 5-18)
Study: 10755315
Drug: Cisplatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (80 mg/m2)
Study: 7717282
Drug: Ibopamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (100 mg 3 times daily)
Study: 2049963
Drug: Oral absorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral absorbable antibiotics (ofloxacin 400 mg/day and amoxicillin 20 g/day)
Study: 2049963
Drug: Oral nonabsorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonabsorbable antibiotics (vancomycin 450 mg/day, tobramycin 450 mg/day, and colistin 4.5 x 10^6 units daily)
Study: 17931461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vildagliptin 100 mg and Simvastatin 80 mg